Market research
ALPIX.PA Pixium Vision SA
PA EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- P/E ratio
- Not available
- Analyst target
- 45
- Dividend yield
- Not available
- Beta
- 0.95
Profile
Company facts
- Exchange
- PA
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- ISIN
- FR0011950641
- P/E ratio
- Not available
- Analyst target
- 45
- Dividend yield
- Not available
- Beta
- 0.95
About
About Pixium Vision SA
Pixium Vision SA, a bioelectronics and brain machine interface technology company, specialized in neuromodulation application. It develops PRIMA System, a bionic vision system for patients with vision loss due to retinal degeneration caused by the dry atrophic form of Age-related Macular Degeneration (AMD); and to treat blindness, which replace the normal physiological function of the eye's photoreceptor cells by electrically stimulating the nerve cells of the inner retina, which then transmit the stimulation to the brain via the intermediary of the optic nerve. The company has collaboration agreements with Stanford University in California, Institute of Ocular Microsurgery in Barcelona, Institut de la Vision in Paris, Moorfields Eye Hospital in London, University Hospital in Bonn, and UPMC in Pittsburgh. Pixium Vision SA was founded in 2011 and is based in Paris, France.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the ALPIX.PA discussion.
5 years, 5 months ago
Pixium Vision SA is currently in a long term downtrend where the price is trading 5.8% below its 200 day moving average.
From a valuation standpoint, the stock is 300.7% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 1095.5.
Finally, its free cash flow fell by 29.9% to $-2M since the same quarter in the previous year.
Based on the above factors, Pixium Vision SA gets an overall score of 0/5.